癌症 cancer - PubMed 文献(第 5 页)
PubMed 共收录约 5,709,791 篇相关文献，本站只列出其中相关度最高的前 50 篇（共 5 页）；要看全部结果、按影响因子 / 分区 / 年份筛选，请前往完整搜索。
本页是「癌症（cancer）」PubMed 检索结果的第 5 页，列出第 41–50 篇相关文献；主题介绍见第 1 页。
癌症 的 PubMed 搜索结果(第 5 页)
-
Clinical approaches to osseous metastases in prostate cancer. 前列腺癌骨转移的临床处理方法
Prostate cancer is unique among solid tumors in its proclivity to metastasize primarily to bone. Osseous metastases pose a formidable health threat to patients with metastatic disease, putting them at risk for pain, marrow crowding, fracture, and other sequelae. Treatments directed against bone disease have the potential both to palliate pain and to increase survival. A number of agents exist that have the potential to palliate the effects of osseous metastases and should be routinely applied in the clinical care of the patient with advanced prostate cancer. These include hormones, bone-seeking radiopharmaceuticals, chemotherapy, and bisphosphonates. Strategies under investigation aim to eradicate bone disease, and not merely palliate symptoms. These approaches combine those listed above with tumor-directed targeting of osseous disease and manipulation of the biology that underlies the cancer's relationship to bone.
-
Glycosylation and Antitumor Immunity. 糖基化与抗肿瘤免疫
Glycosylation and its by-product, the glycan, play a crucial role in many cellular processes. Aberrant glycan structures and mutations of the glycosylation pathway have been intricately linked with the development of cancer and more recently with cancer's ability to escape the innate immune system. This chapter aims to elucidate how glycosylation interacts with the immune system to promote tumor deviation through endogenous lectins, mutated glycosphingolipids, sialic acid domains, and more. This chapter also explores the mechanisms of glycosylation that may lead to powerful translational therapeutic tools, such as glycotransferase inhibitors, glycan/glycopeptide-based vaccines, and antibody-based immunotherapies, all of which have shown great promise clinically in the field of immuno-oncology.
-
The Multifactorial Nature of Cancer's Economic Toll on Patients and Strategies to Mitigate Hardships. 癌症对患者经济负担的多因素性质及减轻困境的策略
This article explores the economic burdens experienced by people with cancer and presents evidence-based solutions to mitigate financial hardships. An analysis of contributing factors like treatment costs and demographic ineq.
-
Vaccinal chronicity: immunotherapy, primary care, and the temporal remaking of lung cancer's patienthood in Cuba. 疫苗性慢性化：免疫治疗、初级保健与古巴肺癌患者身份的时间性重塑
The Cuban biotechnology industry is producing cancer immunotherapy, in particular, therapeutic vaccines that actively stimulate the immune system to stabilise the tumour. These products aim to transform metastatic malignancies into a chronic disease. Since 2010, this therapeutic concept has been integrated within a public health experiment, consisting of the large distribution of immunotherapies, including in primary healthcare centres, to enhance access and assess its effectiveness on a wider population of patients. Such experimental intervention, consisting of post-marketing clinical trials, has focused only on lung cancer, one of the most widespread and lethal cancers on the island. Combining interviews with ethnographic observations focusing on care performed by professionals, patients, and their relatives, this paper analyses the experience of lung cancer chronicity under this type of immunotherapy in Cuba. It shows how a certain form of continuity is made between prophylactic and therapeutic vaccination to shape a new temporality of cancer care, through the integration within primary care, constant access to biotechnology, and multiple care practices directed to strengthen the immunotherapy's efficacy. If vaccinal chronicity remains fragile due to its experimental dimension and the fact that long-term survivorship is still an exceptional phenomenon, lung cancer patienthood is deeply transformed through a shared effort of the people and the state to provide more stable, meaningful, and inclusive care.
-
Attitudes and awareness related to cervical cancer vaccine. 与宫颈癌疫苗相关的态度和认知
Cervical cancer causes major morbidity and mortality around the world. This makes prophylactic vaccines a significant tool for preventing the disease. As these vaccines become more widely available, they have the potential to drastically lower the cancer's prevalence and burden in the future.
-
[Androgens and laryngeal cancer]. [雄激素与喉癌]
The article concerns relations between larynx cancer and androgenic activity in men. Up till now the role of androgens in laryngeal carcinogenesis has not been established. Authors point out to andropenia (gonadal and supracortical) in elderly males and its influence on larynx cancer occurrence in the course of aging. Results of androgen receptor studies in unchanged and neoplastic tissue of the vocal organ are described. There is presented data on serum androgen concentrations in healthy men and patients with laryngeal neoplasms. The necessity of further studies of the larynx cancer's hormone-dependence is underlined.
-
Evolution of Premalignant Disease. 癌前疾病的演变
Where does cancer come from? Although the cell-of-origin is difficult to pinpoint, cancer clones harbor information about their clonal ancestries. In an effort to find cells before they evolve into a life-threatening cancer, physicians currently diagnose premalignant diseases at frequencies that substantially exceed those of clinical cancers. Cancer risk prediction relies on our ability to distinguish between which premalignant features will lead to cancer mortality and which are characteristic of inconsequential disease. Here, we review the evolution of cancer from premalignant disease, and discuss the concept that even phenotypically normal cell progenies inherently gain more malignant potential with age. We describe the hurdles of prognosticating cancer risk in premalignant disease by making reference to the underlying continuous and multivariate natures of genotypes and phenotypes and the particular challenge inherent in defining a cell lineage as "cancerized."
-
RNA-Triggered Chromatin Shredding Hits Cancer's Hardest Targets. RNA触发的染色质粉碎击中癌症最难攻克的目标
RNA-triggered chromatin shredding may offer a new way to attack cancers driven by mutations that have resisted conventional drugs, two new studies show. In mouse models, upon activation by a target transcript, the CRISPR enzyme Cas12a2 can selectively eliminate tumor cells carrying mutations in TP53, MYC, and other hard-to-drug cancer genes.
-
Mechanisms of immune evasion in breast cancer. 乳腺癌中的免疫逃逸机制
Tumors develop multiple mechanisms of immune evasion as they progress, with some cancer types being inherently better at 'hiding' than others. With an increased understanding of tumor immune surveillance, immunotherapy has emerged as a promising treatment strategy for breast cancer, despite historically being thought of as an immunologically silent neoplasm. Some types of cancer, such as melanoma, bladder, and renal cell carcinoma, have demonstrated a durable response to immunotherapeutic intervention, however, breast neoplasms have not shown the same efficacy. The causes of breast cancer's immune silence derive from mechanisms that diminish immune recognition and others that promote strong immunosuppression. It is the mechanisms of immune evasion in breast cancers that are poorly defined. Thus, further characterization is critical for the development of better therapies. This brief review will seek to provide insight into the possible causes of weak immunogenicity and immune suppression mediated by breast cancers and highlight current immunotherapies being used to restore immune responses to breast cancer.
-
Metabolic targets for cancer therapy. 癌症治疗的代谢靶点
Malignant cells exhibit metabolic changes, when compared to their normal counterparts, owing to both genetic and epigenetic alterations. Although such a metabolic rewiring has recently been indicated as yet another general hallmark of cancer, accumulating evidence suggests that the metabolic alterations of each neoplasm represent a molecular signature that intimately accompanies and allows for different facets of malignant transformation. During the past decade, targeting cancer metabolism has emerged as a promising strategy for the development of selective antineoplastic agents. Here, we discuss the intimate relationship between metabolism and malignancy, focusing on strategies through which this central aspect of tumour biology might be turned into cancer's Achilles heel.